Novo Holdings

Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, that specializes in developing biocatalysts for the fermentation of fine chemicals. Founded in 2012, the company utilizes a patent-pending high-throughput screening technology to create biocatalysts with remarkable speed and efficiency. By focusing on tailored biocatalytic processes, Biosyntia enables the production of complex chemical compounds through fermentation, significantly reducing both production costs and environmental impact compared to traditional chemical synthesis methods. The company collaborates with manufacturers of fine chemical compounds, including flavors, fragrances, active pharmaceutical ingredients, pigments, and additives, to promote sustainable manufacturing practices and contribute to a greener future. Biosyntia is located at the Novo Nordisk Foundation Center for Biosustainability, approximately 25 kilometers north of Copenhagen.

NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders. Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise. Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.

Operator of a pioneering private biotech company intended for vivo direct cell reprogramming for cancer immunotherapy. The company's proprietary reprogramming technologies develop gene therapy products that ignite efficient and personalized immune responses to establish a robust pipeline of off-the-shelf cancer immunotherapies, activating personalized anti-cancer immune defenses for the benefit of patients in need by offering new treatment avenues for cancers resistant to conventional methods, enabling patients to acquire new forms of treatment for cancer resistant to conventional treatment methods.

Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.

Chromologics ApS is a Danish biotechnology company based in Søborg, founded in 2017 as a spin-out from the Technical University of Denmark. The company specializes in the development of bio-based solutions for natural food colorants, with a focus on innovative products that can replace existing natural colorants like carmine and betanin. Chromologics has created a fungal biotechnology platform to produce its flagship product, ChromoRed, which represents a new generation of natural red food colorants. Through its advancements, Chromologics aims to provide sustainable alternatives in the food industry.

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.

BioPhero ApS provides bio-based pheromones for pest management. The company was founded in 2016 and is based in Kongens Lyngby, Denmark.

IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.

Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.

Rappta Therapeutics Oy engages in developing anti-cancer drugs that activate protein phosphatase 2A (PP2A). Protein phosphatase 2A (PP2A) is a critical enzyme regulating protein de-phosphorylation and tumor growth. The company was incorporated in 2019 and is based in Helsinki, Finland with an additional office in the United States.

Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.

Chromologics ApS is a Danish biotechnology company based in Søborg, founded in 2017 as a spin-out from the Technical University of Denmark. The company specializes in the development of bio-based solutions for natural food colorants, with a focus on innovative products that can replace existing natural colorants like carmine and betanin. Chromologics has created a fungal biotechnology platform to produce its flagship product, ChromoRed, which represents a new generation of natural red food colorants. Through its advancements, Chromologics aims to provide sustainable alternatives in the food industry.

Reapplix A/S manufactures device for cell therapy that helps patients in wound healing. It offers 3C Patch, a triple layer patch that consists of fibrin for moisture retention and strength, platelets for growth factor release, and leucocytes to orchestrate wound healing and to fight infection. The company was formerly known as Reapplix ApS and changed its name to Reapplix A/S in December 2018. Reapplix A/S was founded in 2008 and is based in Birkerød, Denmark with an additional office in Southlake, Texas.

Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipid uptake in adipose tissue in an efficient manner.

IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.

Draupnir Bio is focused on developing innovative cholesterol-lowering medications aimed at preventing blood clots in the heart with greater efficacy than existing treatments. The company utilizes a platform that explores the glycome to create novel therapeutics, employing advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. This platform enables the synthesis, screening, and selection of potent heparan sulfate glycomimetic drug candidates, targeting cardiovascular, inflammatory, and infectious diseases. Additionally, Draupnir Bio's technology includes the development of protein degraders that can target extracellular disease proteins, potentially addressing a wide range of unmet therapeutic needs across various medical conditions. This approach promises more convenient and accessible treatment options compared to traditional injectable therapies.

Reapplix A/S manufactures device for cell therapy that helps patients in wound healing. It offers 3C Patch, a triple layer patch that consists of fibrin for moisture retention and strength, platelets for growth factor release, and leucocytes to orchestrate wound healing and to fight infection. The company was formerly known as Reapplix ApS and changed its name to Reapplix A/S in December 2018. Reapplix A/S was founded in 2008 and is based in Birkerød, Denmark with an additional office in Southlake, Texas.

STipe Therapeutics focuses on harnessing the innate immune system to battle cancer. The company has developed first-in-class drugs targeting intracellular protein-protein interactions of the STING Pathway; a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders. The company has identified and validated compounds that sensitizes the STING pathway and by this modulates the tumor microenvironment to support a potent anti-tumoral response.

Forendo Pharma is a drug discovery and development company based in Turku, Finland, established in 2013. The company specializes in creating novel therapies for urological and endocrinological diseases, focusing on tissue-specific regulation of sex hormone mechanisms. Its primary product, Fispemifene, is a selective estrogen receptor modulator designed to address the symptoms of low testosterone in men. Additionally, Forendo Pharma is developing a 17HSD1-inhibitor targeting endometriosis, which aims to meet unmet medical needs in both women's and men's health. Through its innovative approach, Forendo Pharma seeks to enhance treatment options for a range of gynecological and urological conditions.

AFYX Therapeutics is changing the way mucosal diseases are treated. They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. Their proprietary Rivelin® patch is flexible, biodegradable, and adhesive to mucosal surfaces. Designed with electrospinning technology, it delivers a therapeutic directly to the site in need, without interfering with patients’ daily activities.

Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.

Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.

Envirotainer AB is engaged in the production, development, and rental of active temperature-controlled containers for air transportation of temperature-sensitive healthcare products in Sweden and internationally. It also provides various services, including laboratory testing, qualification and validation support, data collection and reporting, and the Qualified Envirotainer Program for training. The company’s client list includes pharmaceutical and biotech companies. The company was founded in 1986 and is based in Upplands Väsby, Sweden with operations centers in Singapore; Dallas, Texas; Frankfurt, Germany; and Toronto, Canada. It also has a network stations in Hyderabad, India.

BioPhero ApS provides bio-based pheromones for pest management. The company was founded in 2016 and is based in Kongens Lyngby, Denmark.

Forendo Pharma is a drug discovery and development company based in Turku, Finland, established in 2013. The company specializes in creating novel therapies for urological and endocrinological diseases, focusing on tissue-specific regulation of sex hormone mechanisms. Its primary product, Fispemifene, is a selective estrogen receptor modulator designed to address the symptoms of low testosterone in men. Additionally, Forendo Pharma is developing a 17HSD1-inhibitor targeting endometriosis, which aims to meet unmet medical needs in both women's and men's health. Through its innovative approach, Forendo Pharma seeks to enhance treatment options for a range of gynecological and urological conditions.

Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, that specializes in developing biocatalysts for the fermentation of fine chemicals. Founded in 2012, the company utilizes a patent-pending high-throughput screening technology to create biocatalysts with remarkable speed and efficiency. By focusing on tailored biocatalytic processes, Biosyntia enables the production of complex chemical compounds through fermentation, significantly reducing both production costs and environmental impact compared to traditional chemical synthesis methods. The company collaborates with manufacturers of fine chemical compounds, including flavors, fragrances, active pharmaceutical ingredients, pigments, and additives, to promote sustainable manufacturing practices and contribute to a greener future. Biosyntia is located at the Novo Nordisk Foundation Center for Biosustainability, approximately 25 kilometers north of Copenhagen.

NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders. Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise. Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.

Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.

Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipid uptake in adipose tissue in an efficient manner.

AFYX Therapeutics is changing the way mucosal diseases are treated. They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. Their proprietary Rivelin® patch is flexible, biodegradable, and adhesive to mucosal surfaces. Designed with electrospinning technology, it delivers a therapeutic directly to the site in need, without interfering with patients’ daily activities.

Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.

AMRA is an international medical technology company, the first in the world to transform MR images into precise body composition measurements using a cloud-based, computer-aided service.They collaborate with world-leading pharmaceutical organizations, biobanks and population cohorts, research institutions, hospitals, and clinics, aiding in the advancement of metabolic research and therapeutic application. With more accurate knowledge about our bodies, AMRA assists the world's medical leaders in predicting and preventing disease.

Hoba Therapeutics is developing a new therapeutic protein for the treatment of neuropathic pain.

Battersea Biotech develops alternative cell types and technologies to overcome the shortcomings of current CAR-T and TCR technologies.

Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, specializing in the development of medical treatments for atrial fibrillation (AF), the most common type of cardiac arrhythmia. Founded in 2011, the company focuses on creating SK channel inhibitors, which are designed to be safe and tolerable options for patients. These drugs work by inhibiting specific ion channels in heart cells that are crucial for generating the electrical signals that regulate the heart's rhythm. Acesion Pharma aims to provide effective chronic treatments that prevent the recurrence of AF and help maintain a normal heart rhythm.

Reapplix A/S manufactures device for cell therapy that helps patients in wound healing. It offers 3C Patch, a triple layer patch that consists of fibrin for moisture retention and strength, platelets for growth factor release, and leucocytes to orchestrate wound healing and to fight infection. The company was formerly known as Reapplix ApS and changed its name to Reapplix A/S in December 2018. Reapplix A/S was founded in 2008 and is based in Birkerød, Denmark with an additional office in Southlake, Texas.

NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders. Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise. Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.

Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.

NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders. Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise. Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.

Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, specializing in the development of medical treatments for atrial fibrillation (AF), the most common type of cardiac arrhythmia. Founded in 2011, the company focuses on creating SK channel inhibitors, which are designed to be safe and tolerable options for patients. These drugs work by inhibiting specific ion channels in heart cells that are crucial for generating the electrical signals that regulate the heart's rhythm. Acesion Pharma aims to provide effective chronic treatments that prevent the recurrence of AF and help maintain a normal heart rhythm.

Symphogen A/S is a late-stage biopharmaceutical company based in Ballerup, Denmark, with an operational presence in Somerville, New Jersey. The company specializes in developing innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies (rpAb). Its product pipeline includes Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR for metastatic colorectal cancer and glioblastoma; Sym013, which inhibits EGFR, HER2, and HER3; and Sym015, aimed at eliminating the MET receptor. Additionally, Sym021 is designed to block PD1, while Sym009 is a monoclonal antibody conjugated to an antibiotic for treating resistant strains of staphylococcus aureus. Symphogen targets various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers. Founded in 2000, Symphogen continues to advance its mission in the biopharmaceutical sector.

Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, that specializes in developing biocatalysts for the fermentation of fine chemicals. Founded in 2012, the company utilizes a patent-pending high-throughput screening technology to create biocatalysts with remarkable speed and efficiency. By focusing on tailored biocatalytic processes, Biosyntia enables the production of complex chemical compounds through fermentation, significantly reducing both production costs and environmental impact compared to traditional chemical synthesis methods. The company collaborates with manufacturers of fine chemical compounds, including flavors, fragrances, active pharmaceutical ingredients, pigments, and additives, to promote sustainable manufacturing practices and contribute to a greener future. Biosyntia is located at the Novo Nordisk Foundation Center for Biosustainability, approximately 25 kilometers north of Copenhagen.

Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, specializing in the development of medical treatments for atrial fibrillation (AF), the most common type of cardiac arrhythmia. Founded in 2011, the company focuses on creating SK channel inhibitors, which are designed to be safe and tolerable options for patients. These drugs work by inhibiting specific ion channels in heart cells that are crucial for generating the electrical signals that regulate the heart's rhythm. Acesion Pharma aims to provide effective chronic treatments that prevent the recurrence of AF and help maintain a normal heart rhythm.

Glionova AB is a biopharmaceutical company based in Stockholm, Sweden, focused on developing therapies for challenging cancers. Founded in 2014, the company is working on GLN-1001, an orally bioavailable small molecule designed to selectively induce cell death in glioblastoma cells while sparing normal brain tissue. This innovative approach aims to improve treatment outcomes for patients suffering from glioblastoma, a common and aggressive form of primary brain tumor. In addition to its core product development, Glionova seeks to establish strategic partnerships with global pharmaceutical companies that specialize in oncology to enhance its market presence and advance its therapeutic offerings.

Forendo Pharma is a drug discovery and development company based in Turku, Finland, established in 2013. The company specializes in creating novel therapies for urological and endocrinological diseases, focusing on tissue-specific regulation of sex hormone mechanisms. Its primary product, Fispemifene, is a selective estrogen receptor modulator designed to address the symptoms of low testosterone in men. Additionally, Forendo Pharma is developing a 17HSD1-inhibitor targeting endometriosis, which aims to meet unmet medical needs in both women's and men's health. Through its innovative approach, Forendo Pharma seeks to enhance treatment options for a range of gynecological and urological conditions.

Pulmologix AB develops, manufactures, and sells oral non-steroidal anti-asthmatic drug for the treatment of early onset allergic asthma. The company was founded in 2006 and is based in Stockholm, Sweden.

Sonion A/S design and manufacturing of advanced miniature components and solutions.

Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.

Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.

Symphogen A/S is a late-stage biopharmaceutical company based in Ballerup, Denmark, with an operational presence in Somerville, New Jersey. The company specializes in developing innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies (rpAb). Its product pipeline includes Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR for metastatic colorectal cancer and glioblastoma; Sym013, which inhibits EGFR, HER2, and HER3; and Sym015, aimed at eliminating the MET receptor. Additionally, Sym021 is designed to block PD1, while Sym009 is a monoclonal antibody conjugated to an antibiotic for treating resistant strains of staphylococcus aureus. Symphogen targets various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers. Founded in 2000, Symphogen continues to advance its mission in the biopharmaceutical sector.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.

Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries. It develops and produces cultures, enzymes, probiotics, and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements, and even animal feed. All solutions are based on strong research and development competencies coupled with significant technology investments. Chr. Hansen has more than 2,500 employees in 30 countries and main production facilities in Denmark, France, USA, and Germany. It was founded in 1874 and is listed on Nasdaq Copenhagen.

Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.

Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.

Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.

Symphogen A/S is a late-stage biopharmaceutical company based in Ballerup, Denmark, with an operational presence in Somerville, New Jersey. The company specializes in developing innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies (rpAb). Its product pipeline includes Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR for metastatic colorectal cancer and glioblastoma; Sym013, which inhibits EGFR, HER2, and HER3; and Sym015, aimed at eliminating the MET receptor. Additionally, Sym021 is designed to block PD1, while Sym009 is a monoclonal antibody conjugated to an antibiotic for treating resistant strains of staphylococcus aureus. Symphogen targets various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers. Founded in 2000, Symphogen continues to advance its mission in the biopharmaceutical sector.

Adenium Biotech ApS is a Danish biopharmaceutical company founded in 2011, focused on developing and commercializing innovative antibiotics to address multi-drug resistant bacterial infections. The company specializes in solutions for hospital-acquired infections, particularly complicated urinary tract infections and pneumonia caused by resistant gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Its lead product, Arenicin, is a non-toxic antimicrobial peptide derived from lugworms, demonstrating strong efficacy against gram-negative pathogens. Adenium Biotech employs a semi-virtual model, leveraging a small team of experts and an international scientific advisory board to advance the Arenicin program through clinical development towards regulatory approval. The company's goal is to provide effective treatments for infections that are increasingly difficult to manage due to antibiotic resistance.

Nanoference ApS develops technology that uses nano particles to deliver Sirna molecules directly to the desired part of the body. The company was founded in 2009 and is based in Aarhus, Denmark.

7TM Pharma is a biotech company that discovers and develops drugs with a primary therapeutic focus on diabetes, gastrointestinal, metabolic, asthma, and vascular diseases. The company offers seven transmembrane-spanning receptors, including TM38837, a small molecule CB1 receptor antagonist; TM30339, a NPY Y4 selective agonist that is used within gastrointestinal disorders, and short bowel syndrome; and CRTH2 antagonist, an oral drug for inflammatory or respiratory diseases. 7TM Pharma was founded in 2000 and is based in Lyngby, Hovedstaden.

Celltrix is a Swedish biotechnology/medical device company focusing on reconstructive cosmetic surgery. Research, development and production are based in Malmö. They plan to launch the first product —Credurance — in 2010. Their product represents a new type of dermal filler. An immediate filling effect is achieved and the surrounding cells are presented to a matrix suitable for cell growth. As the cells grow on and inside the matrix, they produce their own environment, natural collagen, which gradually replaces the matrix – biorestoring.

Symphogen A/S is a late-stage biopharmaceutical company based in Ballerup, Denmark, with an operational presence in Somerville, New Jersey. The company specializes in developing innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies (rpAb). Its product pipeline includes Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR for metastatic colorectal cancer and glioblastoma; Sym013, which inhibits EGFR, HER2, and HER3; and Sym015, aimed at eliminating the MET receptor. Additionally, Sym021 is designed to block PD1, while Sym009 is a monoclonal antibody conjugated to an antibiotic for treating resistant strains of staphylococcus aureus. Symphogen targets various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers. Founded in 2000, Symphogen continues to advance its mission in the biopharmaceutical sector.

Symphogen A/S is a late-stage biopharmaceutical company based in Ballerup, Denmark, with an operational presence in Somerville, New Jersey. The company specializes in developing innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies (rpAb). Its product pipeline includes Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR for metastatic colorectal cancer and glioblastoma; Sym013, which inhibits EGFR, HER2, and HER3; and Sym015, aimed at eliminating the MET receptor. Additionally, Sym021 is designed to block PD1, while Sym009 is a monoclonal antibody conjugated to an antibiotic for treating resistant strains of staphylococcus aureus. Symphogen targets various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers. Founded in 2000, Symphogen continues to advance its mission in the biopharmaceutical sector.

Nuevolution AB is a biopharmaceutical company based in Copenhagen, Denmark, founded in 2001. It specializes in developing drug treatments for oncology and chronic inflammatory diseases, leveraging its unique Chemetics platform for drug discovery. This platform combines proven wet chemistry and molecular biology, allowing for the synthesis and screening of over one billion small molecule compounds and synthetic biologics. Nuevolution is focused on several therapeutic programs, including ROR?t inhibitors and IL-17A inhibitors for chronic inflammatory diseases, as well as GRP78 for oncology. The company has established collaborations with notable pharmaceutical partners, including Amgen and Janssen Biotech, and is involved in joint ventures aimed at discovering novel small molecule drugs targeting epigenetic factors. Through its innovative technology, Nuevolution aims to address significant unmet medical needs in various therapeutic areas.

Symphogen A/S is a late-stage biopharmaceutical company based in Ballerup, Denmark, with an operational presence in Somerville, New Jersey. The company specializes in developing innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies (rpAb). Its product pipeline includes Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR for metastatic colorectal cancer and glioblastoma; Sym013, which inhibits EGFR, HER2, and HER3; and Sym015, aimed at eliminating the MET receptor. Additionally, Sym021 is designed to block PD1, while Sym009 is a monoclonal antibody conjugated to an antibiotic for treating resistant strains of staphylococcus aureus. Symphogen targets various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers. Founded in 2000, Symphogen continues to advance its mission in the biopharmaceutical sector.

Fisher BioImage ApS, a life science company, develops and sells assays for monitoring protein translocations and protein interactions in living cells. It provides Redistribution technology, which helps to monitor cell-based protein translocation assays using fluorescent protein reporters. The company offers assays to pharmaceutical and biotechnology companies, as well as to academic groups for basic research.

Nuevolution AB is a biopharmaceutical company based in Copenhagen, Denmark, founded in 2001. It specializes in developing drug treatments for oncology and chronic inflammatory diseases, leveraging its unique Chemetics platform for drug discovery. This platform combines proven wet chemistry and molecular biology, allowing for the synthesis and screening of over one billion small molecule compounds and synthetic biologics. Nuevolution is focused on several therapeutic programs, including ROR?t inhibitors and IL-17A inhibitors for chronic inflammatory diseases, as well as GRP78 for oncology. The company has established collaborations with notable pharmaceutical partners, including Amgen and Janssen Biotech, and is involved in joint ventures aimed at discovering novel small molecule drugs targeting epigenetic factors. Through its innovative technology, Nuevolution aims to address significant unmet medical needs in various therapeutic areas.